



PRESS RELEASE

Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

- A poster evaluating comprehensive correlative science findings from the AFM24 monotherapy phase 1 study (AFM24-101) will be presented
- In a second poster presentation, initial phase 1 dose escalation study results of AFM24 in combination with Roche's checkpoint inhibitor atezolizumab (AFM24-102) will be shown

Heidelberg, Germany, October 5, 2022 – Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that two abstracts with new data on the company's novel innate cell engager (ICE®) AFM24 have been accepted for poster presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The conference will take place on November 8-12, 2022, in Boston, MA.

Poster presentation details

Poster number: 729

Title: Targeting Epidermal Growth Factor Receptor (EGFR)-Expressing Solid Tumors with AFM24, a Novel CD16A Bispecific Innate Cell Engager: Comprehensive Correlative Science Findings from a Phase 1 Study

Authors: Gabriele Hintzen, Susanne Wingert, Michael Emig, Pilar Nava-Parada, Kerstin Pietzko, Laura Kohlhas, Uwe Reusch, Melissa M. Berrien-Elliott, Todd A. Fehniger, Mark Foster, Paolo Nuciforo, Ester Castillo Andreo, Sina Staebler, Paulien Ravenstijn, Bettina Rehbein, Erich Rajkovic, Arndt Schottelius, Joachim Koch

Date, time and location:

The poster session will take place on Thursday, November 10, 2022, from 9:00 a.m. to 9:00 p.m. EST, in the Boston Convention & Exhibition Center, Poster Hall C. Required hours are 11:40 a.m. - 1:10 p.m. and 7:30 - 9:00 p.m. (poster reception).

Poster number: 746

Title: AFM24 and Atezolizumab Combination in Patients with Advanced Epidermal Growth Factor Receptor-expressing (EGFR+) Solid Tumors: Initial Results from the Phase 1 Dose-escalation Study

Authors: Omar Saavedra, Daniela Morales-Espinosa, Juanita Lopez, Eric Christenson, Anthony El-Khoueiry, Andrés Cervantes, Christa Raab, Ulrike Gärtner, Kerstin Pietzko, Laura Kohlhas, Daniel Schütz, Gabriele Hintzen, Paulien Ravenstijn, Michael Emig, Pilar Nava-Parada

Date, time and location:

The poster will be shown on Friday, November 11, 2022, from 9:00 a.m. to 8:30 p.m. EST, in the Boston Convention & Exhibition Center, Poster Hall C. Required hours are: 11:55 a.m. - 1:25 p.m. and 7:00 - 8:30 p.m. (poster reception).

Additional information:

More details about the SITC Annual Meeting program are available at www.sitcancer.org. Full abstracts will be made public on November 7, 2022, 8:00 a.m. EST. In addition, e-posters will be available on the SITC 2022's Virtual ePoster Hall to attendees.

About AFM24

AFM24 is a tetravalent, bispecific innate cell engager (ICE®) that activates the innate immune system by binding to CD16A on innate immune cells and EGFR, a protein widely expressed on solid tumors, to kill cancer cells. Generated by Affimed's fit-for-purpose ROCK® platform, AFM24 represents a distinctive mechanism of action that uses EGFR as a docking site to engage innate immune cells for tumor cell killing through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.

Affimed is evaluating AFM24 as monotherapy and in combinations with other cancer treatments in patients with advanced EGFR-expressing solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

AFM24-101, a monotherapy, first-in-human phase 1/2a open-label, is a non-randomized, multi-center, multiple ascending dose escalation and expansion study. Additional details may be found at www.clinicaltrials.gov using the identifier NCT04259450.

AFM24 is also being evaluated in a phase 1/2a study in combination with Roche's PD-L1 checkpoint inhibitor atezolizumab (AFM24-102, NCT05109442).

Furthermore, Affimed and NKGen Biotech initiated a phase 1/2a study (AFM24-103), investigating AFM24 in combination with NKGen Biotech's NK cell SNK01 (NCT05099549).

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients' immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients' lives. For more about the company's people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact

Alexander Fudukidis
Director, Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

Media Contact

Mary Beth Sandin
Vice President, Marketing and Communications
E-Mail: m.sandin@affimed.com
Tel.: +1 (484) 888-8195